Comparison of the recovery rate of otomycosis using betadine and clotrimazole topical treatment

Mohammad Reza Mofatteh\textsuperscript{a}, Zahra Naseripour Yazdi\textsuperscript{b}, Masoud Yousefi\textsuperscript{c}, Mohammad Hasan Namaei\textsuperscript{b,c,*}

\textsuperscript{a} Birjand University of Medical Science, School of Medicine, Department of Ears, Nose and Throat, Birjand, Iran
\textsuperscript{b} Birjand University of Medical Sciences, School of Medicine, Birjand, Iran
\textsuperscript{c} Birjand University of Medical Science, Infectious Diseases Research Center, Birjand, Iran

Received 21 February 2017; accepted 12 April 2017
Available online 6 May 2017

**KEYWORDS**
Otomycosis;
Topical betadine;
Topical clotrimazole;
Recovery rate

**Abstract**

Introduction: Otomycosis is a common diseases that can be associated with many complications including involvement of the inner ear and mortality in rare cases. Management of otomycosis can be challenging, and requires a close follow-up. Treatment options for otomycosis include local debridement, local and systemic antifungal agents and utilization of topical antiseptics.

Objective: This study was designed to compare the recovery rate of otomycosis using two therapeutic methods; topical betadine (Povidone-iodine) and clotrimazole.

Methods: In this single-blind clinical trial, 204 patients with otomycosis were selected using a non-probability convenient sampling method and were randomly assigned to two treatment groups of topical betadine and clotrimazole (102 patients in each group). Response to treatment was assessed at 4, 10 and 20 days after treatment. Data were analyzed using the independent \( t \)-test, Chi-Square and Fisher exact test in SPSS v.18 software, at a significance level of \( p < 0.05 \).

Results: The results showed that out of 204 patients with otomycosis, fungi type isolated included Aspergillus in 151 cases (74%), and Candida albicans in 53 patients (26%). On the fourth day after treatment, 13 patients (13.1%) in the group treated with betadine and 10 patients (9.8%) in the group treated with clotrimazole showed a good clinical response to treatment (\( p = 0.75 \)). A good response to treatment was reported for 44 (43.1%) and 47 patients (46.1%) on the tenth day after the treatment (\( p = 0.85 \); and 70 (68.6%) and 68 patients (67.6%) on the...
twenty-first day after treatment ($p=0.46$) in the groups treated with betadine and clotrimazole, respectively. The response to treatment was thus not significantly different in the two groups. 

**Conclusion:** In the present study, the efficacy of betadine and clotrimazole was the same for the treatment of otomycosis. The result of this study supports the use of betadine as an effective antifungal in otomycosis treatment, helping to avoid the emergence of resistant organisms.

© 2017 Associação Brasileira de Otorrinolaringologia e Cirurgia Cérvico-Facial. Published by Elsevier Editora Ltda. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
hearing loss. Neck skin and ear cartilage are also affected in acute infections. In chronic cases, a false veil of yeast in different colors (depending on the type of fungus) may occur in the ear canal. The mycosis can have a poor prognosis in immunocompromised individuals, especially in cases of cellular immunodeficiency and neutropenia. The disease presents many challenges, both for patients and for ENT specialists, and may recur despite long-term treatment and follow-up.9,10

The main treatment of otomycosis is the removal of visible debris and fungal elements. Topical medications recommended for the control of this condition include steroids, antiseptics, acidic solutions, antifungal agents and driers. Antifungal medications of otomycosis do not always cure the disease and in addition treatment should improve the physiological signs of external ear canal.12,13 Using boric acid in an alcohol solution for the treatment of disease is associated with 23% recurrence rate. Furthermore, using antifungal solutions, such as clotrimazole or nystatin, may be effective for the treatment of Candida infections, but Aspergillus infections respond poorly to treatment.14,15 This is while a wide range of fungi have been reported to cause otomycosis and the most common species is Aspergillus. Therefore, an appropriate treatment regimen is necessary for treatment. On the other hand, widespread and unnecessary use of antibacterial treatment for medial and external otitis may cause fungal overgrowth in this area, so the adverse effects of using wide-spectrum antibiotics are the secondary overgrowth of fungus and increasing prevalence of otomycosis.16,17

Given the importance of otomycosis treatment as one of the challenges facing ENT specialists, this study aimed to compare the recovery rate of otomycosis using topical betadine and clotrimazole.

Methods
Study group
This single-blind clinical trial was conducted on 204 patients with a definitive diagnosis of otomycosis. After receiving permission from the Ethics Committee of the University and recording in Iranian Registry of Clinical Trials by the registration number (IRCT20141223020484N1), the participants were selected from those referred to the ENT clinic of Imam Reza and Vali-Asr Hospitals of Birjand University of Medical Sciences during the first six months of 2014. Patients with clinical signs and symptoms including pain, itching, mass in the external auditory canal, stuffy feeling associated with hearing loss and discharge were considered suspicious for otomycosis. The objectives of the study were explained to the participants and they were recruited into the study if they were willing to participate and had none of the exclusion criteria, including: otitis media with restriction of external ear canal, chronic mucus from ear, history of ear surgery, history of treatment with antifungal agents and corticosteroids, and external ear anomaly.

After recording the demographic characteristics such as age, sex, and obtaining informed consent, a total of 204 patients with otomycosis were enrolled into the study and recruited into one of the two treatment groups (102 patients in each group) by blocking randomization. All 204 enrolled patients signed informed consent forms.

Collection of samples
Samples were taken by a special speculum from the mass in the ear canal. Furthermore, in the presence of pus and mucus, these were also separated in a sterile container and sent to specialized laboratories of mycology of Birjand University of Medical Sciences (BUMS).

Mycological investigation
In the laboratory, the samples were evaluated by a microbiology specialist using KOH method, and the presence of fungal elements was considered as definite diagnosis of otomycosis. A portion of the sample was spread on a clean slide glass for direct examination and another sample inoculated in the Sabouraud dextrose agar (Merck, Germany) supplemented with chloramphenicol (Fina Daru, Iran) medium for fungal growth. The plates were incubated at room temperature for two weeks. Fungi were identified by standard procedures.18 Furthermore, germ tubes on human sera and production of vesicles on corn meal agar (Merck, Germany) supplemented with tween 80 (Sigma-Aldrich, Germany) were done for the identification of yeast.

Recovery rate of otomycosis
In the study, one patient group was treated with povidone-iodine so that at each visit, the patient’s ear was washed by the physician using 10 mL betadine solution 10% with a syringe. The other group received 8 drops of antifungal clotrimazole, every eight hours. Patients were examined on 4, 10 and 20 days after treatment by an ENT specialist who did not know about the type of treatment. The patients were categorized into three groups based on clinical response: good response (dry external ear canal and the tympanic membrane and lack of secretion), partial response (slight discharge but not dry), and no answer (hypersecretion in the external auditory canal). If complete response, the treatment was discontinued; otherwise treatment was continued. Finally non-responders were considered treatment-resistant on the twentieth day and treatment regimen was continued with Tolnaftate and Violet de gentian.

Statistical analysis
In the present study, to analyze the descriptive data, tables and charts of distribution frequency and for the inferential part, the independent t-test, Chi-square and Fisher exact test were used in SPSS v.18 software. The significant level was considered at $p < 0.05$.

Results
In this study, a total of 204 patients with otomycosis were investigated in two treatment groups of betadine and clotrimazole (102 patients in each group). Overall, 86
(42.15%) of the patients with otomycosis were males and 118 (57.85%) were females. The average age of patients in two groups treated with betadine and clotrimazole was 38.61 ± 15.45 and 40.37 ± 16.15 years old, respectively. In this study, *Aspergillus* spp. was responsible for 75.4% and *Candida albicans* for 24.5% of otomycosis in the patient group treated with betadine. Prevalence of *Aspergillus* spp. and *C. albicans* was reported for 72.5 and 27.5 percentages of patients with otomycosis treated with clotrimazole.

Overall, the study showed no significant difference according to age (*p* = 0.43), sex (*p* = 0.4) and the causative agent of otomycosis (*p* = 0.63) between two treatment groups of betadine and clotrimazole (Table 1).

In the study, recovery rate of otomycosis was evaluated in two treatment groups of betadine and clotrimazole. The results demonstrated that on the fourth day after treatment, 13 patients (13.1%) in the group treated with betadine and 10 patients (9.8%) in the group treated with clotrimazole had a good response to treatment (*p* = 0.75). A good response to treatment was reported for 44 (43.1%) and 47 patients (46.1%) on the tenth day after the treatment (*p* = 0.85); and 70 (68.6%) and 68 patients (67.6%) on the twentieth day after treatment (*p* = 0.46) in the group treated with betadine and clotrimazole, respectively. It is noteworthy that in none of the patients treated with betadine any side effects were observed.

In our study, there was no statistically significant difference in terms of response to treatment in the fourth, tenth and twentieth day after treatment between two treatment groups of betadine and clotrimazole (*p* < 0.05) (Table 2).

### Table 1

| Demographic characteristics | Topical betadine group (%) | Topical clotrimazole group (%) | p-Value |
|-----------------------------|-----------------------------|-------------------------------|--------|
| **Age (years)**<sup>a</sup> | 38.61 ± 15.45               | 40.37 ± 16.15                 | 0.43   |
| **Gender**                  |                             |                               | 0.40   |
| Male                        | 40 (39.2)                   | 46 (45.1)                     |        |
| Female                      | 62 (60.8)                   | 56 (54.9)                     |        |
| **Fungal agent**            |                             |                               | 0.63   |
| *Aspergillus* spp.          | 77 (75.4)                   | 74 (72.5)                     |        |
| *Candida albicans*          | 25 (24.5)                   | 28 (27.5)                     |        |

<sup>a</sup> Values in table are mean ± SD.

### Table 2

| Course of treatment | Type of treatment | Response to treatment | p-Value |
|---------------------|-------------------|-----------------------|--------|
|                     |                   | No response (%)       | Partial response (%) | Good response (%) |        |
| 4 days              | Betadine<sup>a</sup> | 31 (31.3)             | 55 (55.6)             | 13 (13.1)         | 0.75   |
|                     | Clotrimazole      | 32 (31.4)             | 60 (58.8)             | 10 (9.8)          |        |
| 10 days             | Betadine          | 8 (7.8)               | 50 (49)               | 44 (43.1)         | 0.85   |
|                     | Clotrimazole      | 9 (8.8)               | 46 (45.1)             | 47 (46.1)         |        |
| 20 days             | Betadine          | 13 (12.7)             | 19 (18.6)             | 70 (68.6)         | 0.46   |
|                     | Clotrimazole      | 9 (8.8)               | 25 (24.5)             | 68 (66.7)         |        |

<sup>a</sup> Three patients did not attend on the fourth day after the treatment.

### Discussion

Otomycosis is one of the common diseases that are associated with many complications including involvement of the inner ear and mortality in rare cases. The disease presents many challenges, both for patients and for ENT specialists, and may recur despite the concern for long-term treatment and follow-up.<sup>6,11</sup> Results of this study showed that among 204 patients with otomycosis, *Aspergillus* spp. was responsible for 74% (151 cases) and *C. albicans* for 26% (53 patients) of the infection. In the Pradhan et al. study, *Aspergillus* species and *C. albicans* were reported as the most common species of fungi isolated from patients with otomycosis in 2003.<sup>19</sup> The study conducted by Satish and colleagues showed that *Aspergillus* species (77%) was the most commonly isolated fungus in the immunocompetent group while *Candida* (53.4%) was commonly isolated in the immunocompromised group.<sup>20</sup> In another study on 95 patients suspected of having a fungal infection, 72 cases of fungal cultures were positive and *Aspergillus* was identified as the most common fungus grown in culture (41.1%) and *C. albicans* was in the next grade, with a prevalence of 8.2%.<sup>21</sup> The results of our study were consistent with the results above. *Aspergillus* species are one of the most common causes of opportunistic invasive fungal infections, especially otomycosis. This may be due to its high
prevalence in dust and the acidic nature of the ear canal, as *Aspergillus* species grow in pH 5 to 7.21

After completion of the treatment course in the present study, the results showed that on the fourth day after treatment, 55.6% and 58.8% of patients treated with betadine and clotrimazole had partial response to treatment, respectively. In addition, on the tenth day after treatment, 49% of patients treated with povidone-iodine had partial response to treatment, and 46.1% of patients had a good response to treatment with clotrimazole. Finally, on the twentieth day after treatment, 68.6% of patients treated with betadine and 66.7% of patients treated with clotrimazole had good response to treatment. Overall, in our study there was no statistically significant difference in terms of response to treatment in the fourth, tenth and twentieth day after treatment between two treatment groups of betadine and clotrimazole. Regarding the antifungal treatment effect on otomycosis, several studies have been conducted so far. In a single-blind randomized clinical study, the effect of betadine 7.5% in comparison with clotrimazole 1% and lignocaine was evaluated on patients with otomycosis. After the treatment period, in the betadine patients group, the symptoms of itching, discharge from the ear, ear fullness, tinnitus and deafness were treated in 83.3%, 97.1%, 83.3%, 91.7%, and 91.7% of cases, and ear pain was treated in 100% of cases. While, in patients treated with clotrimazole and lignocaine drops, the symptoms of itching, ear discharge and fullness were cured in 93.3%, ear pain in 86.7% and tinnitus in 100% of cases.22 In another study, the therapeutic effect of miconazole ointment and clotrimazole drop was compared in patients with otomycosis. All patients were examined for response to treatment one and two weeks after treatment. The results of the final analysis showed that and there was no difference in terms of response to treatment between the two treatment groups.23 Stern and colleagues demonstrated that clotrimazole was effective against most yeasts and molds but trolnaftate had no impact on otomycosis.24 In another study, clotrimazole and econazol were cited as the drug of choice in the treatment of otomycosis.16

According to the above-mentioned issues, it can be declared that the treatment of otomycosis is today one of the challenges facing ENT specialists, as a great number of fungal infections of external ear are resistant to the available antifungal drugs. Otomycosis treatment requires early detection and timely treatment of patients regarding the possibility of drug resistance in chronic infections. It should be noted that the basis of the treatment of otomycosis is keeping the ear dry and the ear hygiene, and the appropriate treatment protocol should be considered according to the different types of fungi causing the disease and sensitivity to different antifungal drugs.16,27 In our study, clotrimazole and povidone-iodine were used as two drug regimens for treatment of otomycosis. Clotrimazole is a medicine containing azole groups that is used to treat infections. Betadine is also a remedy for infections that is easily accessible and its effect has been proven on chronic suppurative otitis media as the precipitating factors of otomycosis. This drug is a stable, inexpensive substance, and bacterial and fungal resistance to it has not yet been reported. Therefore, betadine can be a good choice for otomycosis treatment in developing countries, due to its low cost, effectiveness and lack of ototoxicity.18,29

**Conclusion**

According to the results, efficacy of betadine and clotrimazole regimens was identical in treatment of otomycosis. Our findings reinforce the use of betadine for otomycosis treatment due to cost-effectiveness and appropriate therapeutic effect on *Aspergillus* species and *C. albicans*, the most common causes of otomycosis. Such treatment can help to avoid the emergence of resistant organisms.

**Conflicts of interest**

The authors declare no conflicts of interest.

**Acknowledgments**

This research was supported by Birjand University of Medical Sciences, Birjand, Iran (Grant no. 657).

**References**

1. Ong Y, Chee G. Infections of the external ear. Ann Acad Med Singapore. 2005;34:330–4.
2. Beers SL, Abramo TJ. Otitis externa review. Pediatr Emerg Care. 2004;20:250–6.
3. Bailey BJ, Johnson JT, Newlands SD. Head & neck surgery- Otolaryngology. Lippincott Williams & Wilkins: 2006.
4. Buchman C, Levine J, Balkany T, Lee K. Infections of the ear. Essential Otolaryngology, Head & Neck Surgery; 2003. p. 462–511.
5. Ho T, Vrabc JT, Yoo D, Coker NJ. Otomycosis: clinical features and treatment implications. Otolaryngol Head Neck Surg. 2006;135:787–91.
6. Moghadam AY, Asadi MA, Dehghani R, Zarei A. Evaluating the effect of a mixture of alcohol and acetic acid for otomycosis therapy. Jundishapur J Microbiol. 2010;3:66–70.
7. Kazemi A, Majidinia M, Jaafari A, Mousavi SAA, Mahmoudabadi AZ, Alikhah H. Etiologic agents of otomycosis in the North-Western area of Iran. Jundishapur J Microbiol. 2015;8:21776.
8. Vlastarakos PV, Nikolopoulos TP, Manolopoulos L, Ferekidis E, Kretasas G. Treating common ear problems in pregnancy: what is safe. Eur Arch Otorhinolaryngol. 2008;265:139–45.
9. Deguine C, Pulec JL. Otomycosis with pus. (Otoplastic Clinic). Ear Nose Throat J. 2002;8:428–9.
10. Pontes 2BVIS, Silva ADf, Lima EdO, Guerra MdH, Oliveira NMC, Carvalho MdFFP, et al. Otomycosis: a retrospective study. Braz J Otorhinolaryngol. 2009;75:367–70.
11. Munguia R, Daniel SJ. Otopathological antifungals and otomycosis: a review. Int J Pediatr Otorhinolaryngol. 2008;72:453–9.
12. Forgie S, Zhanel G, Robinson J. Management of acute otitis media. Paediatr Child Health. 2009;14:457–64.
13. Kiakojuri K, Roushan MRH, Sepidgar SAA. Suction clearance and topical miconazole versus the same combination with acetic drops in the treatment of otomycosis. Southeast Asian J Trop Med Public Health. 2007;38:749–53.
14. Ozcan KM, Ozcan M, Karaarslan A, Karaarslan F. Otomycosis in Turkey: predisposing factors, aetiology and therapy. J Laryngol Otol. 2003;117:39–42.
15. Brant J, Ruckenstein M. Infections of the external ear. Cummings otorhinolaryngology: head and neck surgery. 6th ed Philadelphia (PA): Elsevier Saunders; 2015. p. 2115–22.
16. Berjis N, Okhovat SA, Koujani ZS, Baradaran S. Comparing the therapeutic effect of clotrimazole and trolnaftate in treating
variety of fungal species producing otomycosis in Alzahra and Kashani Hospitals, Iran. J Isfahan Med Sch. 2012;29:1–12.
17. Jackman A, Ward R, April M, Bent J. Topical antibiotic induced otomycosis. Int J Pediatr Otorhinolaryngol. 2005;69:857–60.
18. Fischer F, Cook M, Fischer F, Cook M. Some opportunistic fungi and yeasts and yeast-like fungi. Fund Diagn Mycol. 1998:35–225.
19. Pradhan B, Tuladhar NR, Amatya RM. Prevalence of otomycosis in outpatient department of otolaryngology in Tribhuvan University Teaching Hospital, Kathmandu, Nepal. Ann Otol Rhinol Laryngol. 2003;112:384–7.
20. Satish H, Vishwanatha B, Manjuladevi M. A clinical study of otomycosis. IOSR J Dental Sci (IOSR-JDMS). 2013;5:57–62.
21. Kakkar M, Aggarwal AK, Mathur MD. Otomycosis: a clinicomycological study. Ear Nose Throat J. 2000;79:606–9.
22. Yehia M, Al-Habib H, Shehab N. Otomycosis: a common problem in north Iraq. J Laryngol Otol. 1990;104:387–9.
23. Philip A, Thomas R, Job A, Sundaresan VR, Anandan S, Albert RR. Effectiveness of 7.5 percent povidone iodine in comparison to 1 percent clotrimazole with lignocaine in the treatment of otomycosis. ISRN Otolaryngol. 2013.
24. Alnawaiseh S, Almomani O, Alassaf S, Elessis A, Shawakfeh N, Altubeshi K, et al. Treatment of otomycosis: a comparative study using miconazole cream with clotrimazole otic drops. J Royal Med Ser. 2011;18:34–7.
25. Stern JC, Lucente FE, Shah MK. In vitro effectiveness of 13 agents in otomycosis and review of the literature. Laryngoscope. 1988;98:1173–7.
26. Bassiouny A, Kamel T, Moawad M, Hindawy D. Broad spectrum antifungal agents in otomycosis. J Laryngol Otol. 1986;100:867–73.
27. Kazemi A, Ghiasi S. Survey of otomycosis in north-western area of Iran (1447–2004). J Mazandaran Univ Med Sci. 2005;15:112–9.
28. Jaya C, Job A, Mathai E, Antonisamy B. Evaluation of topical povidone-iodine in chronic suppurative otitis media. Arch Otolaryngol Head Neck Surg. 2003;129:1098–100.
29. Wong CA, Wilson PD, Chew TA. Povidone-iodine in the treatment of metronidazole-resistant Trichomonas vaginalis. Aust NZ J Obstet Gyn. 1990;30:169–71.